BackgroundThe frequency of hyperkalemia in patients with heart failure with reduced ejection fraction (HFrEF) receiving a high percentage of quadruple guideline-directed medical therapy (GDMT) has not
Introduction: The impact of the new potassium binder sodium zirconium cyclosilicate (SZC) on the real-world management of acute hyperkalemia remains unknown. The aim of this study was to evaluate chan